Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Coagulation01:09

Coagulation

9.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.2K
Coagulation01:06

Coagulation

983
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
983
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review.

Journal of clinical medicine·2025
Same author

Intersecting Pathways: The Impact of Philadelphia-Negative Chronic Myeloproliferative Neoplasms on the Pathogenesis and Progression of Heart Failure with Preserved Ejection Fraction.

Diagnostics (Basel, Switzerland)·2025
Same author

Surgical Versus Conservative Management of Supratentorial ICH: A Single-Center Retrospective Analysis (2017-2023).

Journal of clinical medicine·2025
Same author

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.

Journal of clinical medicine·2025
Same author

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.

Current issues in molecular biology·2024
Same author

Incidence of Subclinical Deep Vein Thrombosis after Total Hip and Knee Arthroplasty Is Not Correlated with Number of Tranexamic Acid Doses.

Journal of clinical medicine·2024

Related Experiment Video

Updated: Dec 9, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Coagulation disorders in SARS-CoV-2 infection.

Romeo Gabriel Mihaila1, Marius Dragos Mihaila2

  • 1Faculty of Medicine, "Lucian Blaga" University of Sibiu, and Department of Hematology, CVASIC Laboratory, Emergency County Clinical Hospital Sibiu, Romania.

Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
|September 9, 2020
PubMed
Summary

COVID-19 significantly impacts blood coagulation, causing dysfunction and thrombosis in many patients. Understanding these mechanisms is crucial for effective patient management and personalized anticoagulant therapy.

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

Related Experiment Videos

Last Updated: Dec 9, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

Area of Science:

  • Internal Medicine
  • Pathology
  • Hematology

Background:

  • COVID-19 pathogenesis involves complex mechanisms, including significant coagulation dysfunction.
  • Inflammation, complement activation, cytokine storm, and renin-angiotensin-aldosterone system disruption contribute to thrombotic events in COVID-19 patients.

Purpose of the Study:

  • To elucidate the pathogenetic mechanisms of coagulation disorders in SARS-CoV-2 infection.
  • To highlight the clinical implications of hypercoagulability and thrombosis in COVID-19.
  • To emphasize the importance of personalized anticoagulant treatment strategies.

Main Methods:

  • Review of pathogenetic mechanisms linking SARS-CoV-2 infection to coagulation disorders.
  • Analysis of clinical data and laboratory markers associated with thrombosis.
  • Discussion of thrombelastographic findings in hypercoagulable states post-COVID-19.

Main Results:

  • SARS-CoV-2 infection induces systemic procoagulant activity, leading to intravascular microthrombi and multiorgan failure.
  • Approximately 20% of COVID-19 patients exhibit significant coagulation disorders, with a quarter of ICU patients developing thrombosis despite prophylaxis.
  • Hypercoagulability, evidenced by accelerated clot formation and increased clot strength, persists even after immunization.
  • Key markers include decreased platelets, increased INR, fibrin degradation products, and elevated D-dimers, predicting poor outcomes.

Conclusions:

  • Coagulation dysfunction is a critical factor in COVID-19 morbidity and mortality.
  • Personalized prophylactic or curative anticoagulant treatment, guided by clinical and laboratory monitoring, is essential for managing COVID-19-associated thrombosis.